Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes
Mesothelioma treatment delays that happened because of the COVID-19 pandemic will probably impact survival rates for some patients. A new study of Canadian lung cancer patients found that more than half of them stopped or delayed treatment because of concerns about the virus this spring. Pleural mesothelioma is a lung-related cancer. Like lung cancer patients, mesothelioma patients face a higher risk of virus-related complications because they already have breathing problems. But mesothelioma is also a fast-growing cancer. Most patients get several kinds of treatment at the same time. Mesothelioma treatment delays may give tumors a chance to grow unchecked. A Catch-22 for Mesothelioma Patients Mesothelioma patients and others with lung diseases have had to make some difficult decisions because of … Continue reading Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes
Medical Appointments for Advanced Mesothelioma Patients: How Much is Too Much?
A pair of researchers in New Zealand say the typical number of in-person medical appointments for people with untreatable pleural mesothelioma may be more stressful than helpful. Their study focused on lung cancer and pleural mesothelioma patients with no active treatment options. They found that what most of these patients really want is reliable information, hope, and a positive relationship with their medical team. The report suggests that doctors could meet many of these with fewer visits or virtual medical appointments. Coping with Advanced Mesothelioma Malignant pleural mesothelioma is a rare but highly aggressive lung-related cancer. Mesothelioma starts on the lining around the lungs. It can quickly spread into the lungs and to other organs in the chest. Most patients … Continue reading Medical Appointments for Advanced Mesothelioma Patients: How Much is Too Much?
Keytruda and Tumor Treating Fields: New Hope for Mesothelioma?
There is hope that a new lung cancer trial combining Keytruda and Tumor Treating Fields could lead to a new treatment for pleural mesothelioma. Recent studies show Keytruda (pembrolizumab) is one of the most promising immunotherapy drugs against malignant mesothelioma. Electrical device Tumor Treating Fields is only the second treatment to receive FDA approval for mesothelioma. This summer, the manufacturers of these two treatments announced they would team up. They will test Keytruda and Tumor Treating Fields in patients with non-small cell lung cancer. The results could impact the future of mesothelioma treatment, too. Two Promising Therapies: Keytruda Keytruda is an immunotherapy drug. It blocks a protein called PD-1. Many types of cancer cells overproduce PD-1 to evade the immune … Continue reading Keytruda and Tumor Treating Fields: New Hope for Mesothelioma?
Could Anti-Malaria Drug Become New Pleural Mesothelioma Treatment?
A new report suggests an anti-malaria drug called quinacrine has potential as a new pleural mesothelioma treatment. Before chloroquine became more popular, quinacrine was widely used to treat malaria. Now doctors mostly use it for a diarrhea disease caused by a parasite. But a report published in the International Journal of Molecular Science says quinacrine also has anti-cancer properties. Laboratory tests suggest it has the makings of a powerful new pleural mesothelioma treatment. The Challenge of Pleural Mesothelioma Malignant mesothelioma starts on the membranes around internal organs. It can quickly spread to other parts of the body. Pleural mesothelioma grows on the lining around the lungs. It is almost always caused by exposure to asbestos dust. Most people with mesothelioma … Continue reading Could Anti-Malaria Drug Become New Pleural Mesothelioma Treatment?
Pleural Mesothelioma Rates Expected to Decline Just as Lung Cancer Deaths Have
A new report suggests that pleural mesothelioma rates will continue to decline worldwide over the next decade as many countries get wise to the dangers of asbestos. The report comes on the heels of another study showing dramatic declines in US lung cancer deaths. The report on mesothelioma rates comes from market research website, Research and Markets. The company evaluated malignant pleural mesothelioma incidence in seven countries to come up with an 11-year forecast. According to the research, the US, UK, Japan, and four European countries can expect declining rates of asbestos cancer through 2030. Those who do receive a pleural mesothelioma diagnosis may benefit from some of the same drugs that are helping lung cancer patients survive. Lung Cancer … Continue reading Pleural Mesothelioma Rates Expected to Decline Just as Lung Cancer Deaths Have
Low Dose Aspirin Could Increase Mesothelioma Risk
If you are at risk for malignant mesothelioma, you may want to think twice about taking low dose aspirin on a regular basis. A new study suggests that low dose aspirin could speed up the growth and spread of cancer cells in older people. The study appears in the Journal of the National Cancer Institute. It involved more than 19,000 people in Australia and the US. Low Dose Aspirin and Mesothelioma Many older people take small daily doses of aspirin to reduce their risk for heart attack. Aspirin reduces inflammation and the blood’s ability to clot. This makes it less likely to form the blockages that cause heart attacks and strokes. But mounting evidence suggests that taking low dose aspirin … Continue reading Low Dose Aspirin Could Increase Mesothelioma Risk
The Peritoneal Cancer Index in Mesothelioma Prognosis
The peritoneal cancer index is a valuable prognostic tool and should be considered in mesothelioma treatment planning. That is the word from a group of Finnish cancer researchers. They analyzed twelve years of data on peritoneal mesothelioma in their country. Mesothelioma patients with a higher peritoneal cancer index had a worse prognosis than those with a lower PCI. The group says cancer doctors ought to be including the PCI in their decision-making for people with peritoneal mesothelioma. What is the Peritoneal Cancer Index? Peritoneal mesothelioma makes up about a fifth of all mesothelioma cases. It grows on the peritoneum, a membrane that surrounds the abdominal organs. As cancer spreads, tumors can show up in other areas inside the peritoneal cavity. … Continue reading The Peritoneal Cancer Index in Mesothelioma Prognosis
Decisions About Pleural Effusion in Mesothelioma: New Tool May Help
Researchers in the UK have developed a new tool that may help patients with mesothelioma and other pleural cancers make decisions about pleural effusion. Pleural effusion is the buildup of excess fluid in the space around the lungs. It is a common side effect in people with advanced lung or breast cancer or pleural mesothelioma. It can be complicated and time-consuming to make decisions about pleural effusion treatment. There are many different ways to handle the problem. The UK research team developed a web-based decision support tool with input from patients, clinicians, and caregivers. The tool uses videos and questions to help patients decide on the best course of treatment for their unique situation. Pleural Effusion and Treatment Options The pleura … Continue reading Decisions About Pleural Effusion in Mesothelioma: New Tool May Help
Triple Therapy May Become New First-Line Treatment for Mesothelioma
A combination of three powerful mesothelioma therapies could become a new first-line treatment for mesothelioma if an upcoming clinical trial is successful. The makers of the experimental immunotherapy drug ONCOS-102 announced the new clinical trial. It will enroll up to 100 mesothelioma patients from around the world. The trial will test ONCOS-102 along with Keytruda (pembrolizumab) and standard chemotherapy. Keytruda is an immune checkpoint inhibitor. Both ONCOS-102 and Keytruda have shown some promise when combined with mesothelioma chemotherapy. Targovax hopes that the triple therapy approach will produce an even more powerful first-line treatment for mesothelioma. Clinic Trial of ONCOS-102 A first-line treatment is a treatment for mesothelioma patients who have not yet had any other therapies. Most patients start with … Continue reading Triple Therapy May Become New First-Line Treatment for Mesothelioma
Managing Mesothelioma During the COVID-19 Pandemic: New Guidelines
New guidance suggests that patients should continue to receive treatment for malignant mesothelioma during the COVID-19 pandemic. Two new reports include recommendations for hospitals to keep vulnerable patients safe. COVID-19 is especially dangerous for people with lung-related cancers like pleural mesothelioma. Their immune systems are not as strong as healthy people and their lungs are already damaged. But two new reports suggests that it may be even riskier to put off treatment for lung cancers like mesothelioma during the COVID-19 pandemic. How the Virus Could Impact Lung Cancer Patients Both of the new reports come from researchers in Pennsylvania. They focus on people with lung cancer rather than mesothelioma. But pleural mesothelioma is also a lung-related cancer. It carries many … Continue reading Managing Mesothelioma During the COVID-19 Pandemic: New Guidelines
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!